Citeline Podcasts

Citeline
  • 4.1 (28)
  • BUSINESS
  • UPDATED DAILY
Citeline Podcasts

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.

  1. Scrip M&A Podcast: Looking at M&A activity as Q1 2025 nears a close.

    2D AGO

    Scrip M&A Podcast: Looking at M&A activity as Q1 2025 nears a close.

    Scrip senior writer Joseph Haas discusses the latest biopharmaceutical merger-and-acquisition activity and trends with attorneys Jessica Bisignano and Gabrielle Witt of Hogan Lovells.

    23 min
  2. The Generics Bulletin Podcast: Stelara Biosimilar Launches In The US

    2D AGO

    The Generics Bulletin Podcast: Stelara Biosimilar Launches In The US

    Generics Bulletin editors Dave Wallace and Dean Rudge discuss the latest updates on Stelara (ustekinumab) biosimilars in the US, including recent launches, pricing strategies, and parallels with the biosimilar Humira (adalimumab) experience.

    17 min
  3. Vaccines, Viruses & Variants: The State of COVID-19 & Flu in 2025

    2D AGO

    Vaccines, Viruses & Variants: The State of COVID-19 & Flu in 2025

    Summer Colling and Emma Wille speak with Datamonitor Healthcare's infectious disease analysts Charlotte Holmes and Natasha Boliter to discuss the latest trends in COVID-19 and influenza, including their global impact, vaccine developments, and the challenges in prevention. The experts break down the science behind these viruses, the future of combination vaccines, and what’s next for respiratory disease prevention.

    23 min
  4. Scrip's Five Must-Know Things - 10 March 2025

    3D AGO

    Scrip's Five Must-Know Things - 10 March 2025

    Audio roundup of selected biopharma industry content from Scrip over the business week ended 7 March 2025. In this episode: low-cost Wegovy an alternative for US self-payers; Bayer rolls up sleeves for turnaround; taking the pulse of NewCo creation; the outlook for Alzheimer’s; and India’s rare disease landscape. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-HRMLFN6ZKBHU5KRWSZLLCL3VYY/ Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things Release date: 3 March 2025

    16 min
  5. Women’s Health Innovation And Beyond, With Maxwellia’s Anna Maxwell

    3D AGO

    Women’s Health Innovation And Beyond, With Maxwellia’s Anna Maxwell

    Summary: The UK’s Maxwellia has been on quite a journey, from “switch-in-a-box” start-up to a consumer healthcare company in its own right, launching some of the most innovative products on the way. Specialising so far in women’s health, with OTC brands ranging from the first-in-class daily contraceptive pill to much needed menstrual health solutions, Maxwellia CEO Anna Maxwell now has her eye on a recently published list of Rx-to-OTC switched the UK government would like to see applications for. To realise these switches, Maxwell calls for the government to make it easier for smaller companies like Maxwellia to access all important funding. Timeline 2:00 – Introductions 3:00 – Maxwellia’s growth journey 11:00 – Innovating in women’s health 20:00 – Room for growth in the women’s health category 21:00 – UK government’s Rx-to-OTC switch wishlist 25:00 – The advantages of being a small company 27:00 – Beyond women’s health 30:00 – The disadvantages of being a large company 31:20 – Maxwellia’s immediate future Guest Bio Anna Maxwell is a pioneering pharmacist and healthcare entrepreneur reshaping public health by making essential medicines more accessible. As founder and CEO of Maxwellia, she’s driving growth with strong retail partnerships, a robust innovation pipeline, and plans for international expansion. With a clear vision and relentless drive for innovation, Maxwell is leading a movement to give people more control over their health – “because the future of self-care is here, and Maxwellia is making it happen.”

    36 min
  6. Drug Fix: What We Learned From US FDA Commissioner Nominee Makary’s Confirmation Hearing?

    6D AGO

    Drug Fix: What We Learned From US FDA Commissioner Nominee Makary’s Confirmation Hearing?

    Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith, Senior Editor Sue Sutter, and Editor-in-Chief Nielsen Hobbs discuss the issues that dominated the Senate confirmation hearing for US Food and Drug Administration Commissioner nominee Martin Makary, including vaccines (1:03) and mifepristone (14:45), as well as several questions that were not asked (23:31). They also consider the potential impact of his answers on the agency. More On These Topics From The Pink Sheet Makary Plans To Review Mifepristone Data, Raising Concerns Of Abortion Pill Access Rollbacks: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/makary-plans-to-review-mifepristone-data-raising-concerns-of-abortion-pill-access-rollbacks-24NTRIXLKJD23OKNBB5Z7UAFL4/ Senators Scrutinize US FDA Commissioner Nominee Makary Over VRBPAC Cancellation: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/senators-scrutinize-us-fda-commissioner-nominee-makary-over-vrbpac-cancellation-HVW5VNH55ZFUPBL64BK2VNOYJA/ Science Vs. Politics: Hearing Could Reveal Makary’s Approach To Unusual Administration Involvement: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/science-vs-politics-hearing-could-reveal-makarys-approach-to-unusual-administration-involvement-LGWBJEWWNRCIXPVEJ4AEAJRLN4/

    33 min
  7. Grove AI and Grace, An Agentic AI For Clinical Trial Engagement

    6D AGO

    Grove AI and Grace, An Agentic AI For Clinical Trial Engagement

    In Vivo spoke with Tran Le and Sohit Gatiganti, co-founders of Grove AI and developers of Grace, a voice-based agentic AI that streamlines clinical trial processes.

    19 min
  8. 【3分で解説 世界のファーマ】第23回 トランプ関税 製薬への影響は (Japanese-language podcast)

    6D AGO

    【3分で解説 世界のファーマ】第23回 トランプ関税 製薬への影響は (Japanese-language podcast)

    世界の製薬ビジネスを伝える「Scrip」と、各国で変化する製薬関連の規制に特化した「Pink Sheet」。普段は英語で発信する2つのオンラインメディアから、今注目の話題を日本語で短くまとめてお届けします。 今回取り上げた記事はこちら 「As Trumps Ups The Ante On Tariffs, Reactions Are Mixed（邦訳：止まらぬトランプ関税措置　業界の反応は複雑化）」 URL:　 https://insights.citeline.com/scrip/business/manufacturing/as-trumps-ups-the-ante-on-tariffs-reactions-are-mixed-7WMIGZ3O5JHF7AJSICVLRUE3GY/ ※全文の閲覧には購読（有料）が必要です。 世界の製薬ビジネスメディアScrip（スクリップ）とは？ https://www.citeline.com/ja-jp/products-services/commercialization/scrip

    3 min
See All (518)

4.1
out of 5
28 Ratings

About

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.

Information

  • Creator
    Citeline
  • Years Active
    2014 - 2025
  • Episodes
    518
  • Rating
    Clean
  • Copyright
    © All rights reserved
  • Show Website
    Citeline Podcasts

You Might Also Like

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes, and get the latest updates.
Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada